The Board of Directors of the biotechnology company Aker BioMarine ASA asks its Annual Shareholders’ Meeting to authorise to obtain a subordinated convertible loan of up to MNOK 700. This will provide financial strength for further development of the company’s plans within international growth markets.
The request for such authorisation will be presented at the Annual Shareholders’ Meeting of Aker BioMarine on April 3, 2008.

Aker BioMarine wishes to secure the financing of its plans in order to fulfill the company’s ambitions of being a driving force in the bio marine industry. This encompasses that Aker BioMarine will focus on marine biotechnology, the development of superior ingredients from marine resources, and being a leading international biotechnology company, says Helge Midttun, CEO of Aker BioMarine.

In the year 2008, Aker BioMarine seeks to establish solid demand for its krill-based products Superba™ and Qrill™ in international growth markets, says Midttun.
The dietary supplement Superba™ will be launched in the US this month. The first commercial production of Superba™ undertaken in New Zealand provided a product which is on the preset specification. A launch of Superba™ in the Norwegian market is scheduled for the second quarter of 2008.
Superba™ contains high concentrations of Omega-3 as marine phospholipids and the antioxidant astaxanthin. These are bioactive ingredients with documented and positive effects on health.
Within aquaculture Qrill™Meal has shown good results, and this month will also see the launch of Qrill™Oil towards the animal market.
For further information please contact:
Helge Midttun, CEO, Aker BioMarine, tlf 913 35 790
Nils Brendemo, CFO, Aker BioMarine, tlf 915 48 015